For example, the IgTT-4E1-S antibody, targeting PD-L1, EGFR, and 4-1BB, enables selective PD-L1 blockade and conditional 4-1BB activation in EGFR+ tumor cells. This evidence concerns the gene CD274 and neoplasm.